This review is a summary of an individual study; the XANTUS study. It was the first large, international, prospective study to collect real-world safety and efficacy data on rivaroxaban use in the non-valvular atrial fibrillation (NVAF) setting.
Independent commentary is provided by Dr Christopher Hammett, an Interventional Cardiologist at the Royal Brisbane and Women’s Hospital (RBWH).
Please login below to download this issue (PDF)